Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment

Blood

Volumn 124, Issue 15, 2014, Pages 2467-2468

  Pawlyn, Charlotte ^a,b   Khan, Mohid S ^b,c   Muls, Ann ^b   Sriskandarajah, Priya ^b   Kaiser, Martin F ^a,b   Davies, Faith E ^a,b   Morgan, Gareth J ^a,b   Andreyev, H Jervoise N ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; COLESEVELAM; LENALIDOMIDE; BILE ACID; THALIDOMIDE;

ADULT; AGED; BACTERIAL OVERGROWTH; BILE ACID MALABSORPTION; BREATH ANALYSIS; CLINICAL ARTICLE; DEFECATION HABIT; DIARRHEA; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FAT INTAKE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LETTER; LOW FAT DIET; MALABSORPTION; MALE; MYELOMA; PATIENT REFERRAL; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMPLICATION; MALABSORPTION SYNDROMES; METABOLISM; MIDDLE AGED; MULTIPLE MYELOMA;

AGED; BILE ACIDS AND SALTS; DIARRHEA; FEMALE; HUMANS; MALABSORPTION SYNDROMES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 84908065767     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-06-583302     Document Type: Letter

References (10)

1. Andreyev HJ, Benton BE, Lalji A, et al. Algorithm-based management of patients with gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): a randomised controlled trial. Lancet. 2013;382(9910):2084-2092.
2. San-Miguel JF, Dimopoulos MA, Stadtmauer EA, et al. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk. 2011;11(1):38-43.
3. Dimopoulos MA, Palumbo A, Attal M, et al; European Myeloma Network. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia. 2011;25(5):749-760.
4. Facon T, Dimopoulos MA, Dispenzieri A, et al. Initial phase 3 results of the First (Frontline Investigation of Lenalidomide 1 Dexamethasone versus Standard Thalidomide) trial (MM-020/IFM 07 01) in newly diagnosed multiple myeloma (NDMM) patients (Pts) ineligible for stem cell transplantation (SCT) [abstract]. Blood. 2013;122(21):2.
5. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106(13):4050-4053.
6. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108(10):3458-3464.
7. Bajor A, Kilander A, Sjövall H, Rudling M, Ung KA. The bile acid turnover rate assessed with the (75)SeHCAT test is stable in chronic diarrhoea but slightly decreased in healthy subjects after a long period of time. Dig Dis Sci. 2008; 53(11):2935-2940.
8. Walters JR. Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2014;11(7):426-434.
9. Muls A, Watson L, Shaw CE, Andreyev HJN. Managing gastrointestinal symptoms after cancer treatment: a practical approach for gastroenterologists. Frontline Gastroenterol. 2013(4):57-68.
10. Andreyev HJ, Davidson SE, Gillespie C, Allum WH, Swarbrick E; British Society of Gastroenterology; Association of Colo-Proctology of Great Britain and Ireland; Association of Upper Gastrointestinal Surgeons; Faculty of Clinical Oncology Section of the Royal College of Radiologists. Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer. Gut. 2012;61(2):179-192.